 |
Dantrium® IV
(dantrolene sodium for injection)
Product Summary
Therapeutic Area:
Hospital Products
This product is distributed by: JHP
Pharmaceuticals, LLC
MSDS Sheet
Malignant hyperthermia (MH), an event triggered in susceptible individuals by various anesthetics, is a sudden and life threatening condition. The Malignant Hyperthermia Association of the United States (MHAUS) recommends a minimum stocking level of 36 vials of dantrolene sodium for injection (Dantrium® IV) for facilities that use triggering agents. This number is based on the amount of Dantrium® IV used to treat an MH episode for the average adult (70 kg). However, the size of the patient and the severity of the reaction will dictate the number of vials needed. If you would like to order educational materials on how to prepare your facility for an MH crisis, please contact MHAUS at 800-98-MHAUS.
Description
Dantrium® IV
is a sterile, non-pyrogenic, lyophilized formulation of dantrolene sodium for injection. Dantrium® IV is supplied in 70 mL vials containing 20 mg dantrolene sodium, 3000 mg mannitol, and sufficient sodium hydroxide to yield a pH of approximately 9.5 when reconstituted with 60 mL sterile water for injection USP (without a bacteriostatic agent).
Indications and Usage
Dantrium® IV
is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crisis in patients of all ages.
Dantrium® IV
is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
Contraindications
None
Warnings
The use of
Dantrium® IV
in the management of malignant
hyperthermia crisis is not a
substitute for previously known
supportive measures. These measures
must be individualized, but it will
usually be necessary to discontinue
the suspect triggering agents,
attend to increased oxygen
requirements, manage the metabolic
acidosis, institute cooling when
necessary, monitor urinary output,
and monitor for electrolyte
imbalance.
Adverse Reactions
There have been occasional reports of death following malignant hyperthermia crisis even when treated with intravenous dantrolene.
Adverse events with
Dantrium® IV
include loss of grip strength, weakness in the legs, drowsiness, dizziness, thrombophlebitis, and tissue necrosis/injection site reactions secondary to extravasation. There have been rare reports of pulmonary edema, uticaria and erythema.
Please see the full
prescribing information link above for additional information.
 |
Documents marked with this
icon are presented in
Portable Document Format
(PDF) to retain the original
format. To view or print
this document, you must use
the Adobe® Acrobat® Reader®.
Acrobat® Reader® is free and
available directly from
Adobe’s Web site with full
installation instructions.
You can either view and
print this document or save
it to your computer’s hard
drive to open later. Your
method may vary depending on
your operating system and
browser type.
"Adobe" and "the Adobe logo"
are either registered
trademarks or trademarks of
Adobe Systems Incorporated
in the United States and/or
other countries. |
| |
Return To The Products
Listings Page
»
|
 |
| |
Dantrium® IV
the rapidly mixing product
(dantrolene sodium for injection)
For more information visit
www.dantrium.com
|
|
